Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama

被引：0
|
作者：
Castillo-Fernandez, Omar O.
Lim, Maria
Montano, Lilian
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-05-35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-05-35
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish A.
    Trivedi, Meghana V.
    PHARMACOECONOMICS, 2023, 41 (06) : 709 - 718
  • [2] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in the United States.
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish
    Trivedi, Meghana
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
    Prajakta P. Masurkar
    Haluk Damgacioglu
    Ashish A. Deshmukh
    Meghana V. Trivedi
    PharmacoEconomics, 2023, 41 : 709 - 718
  • [4] CDK4/6 inhibitors in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: An updated network meta-analysis and cost-effectiveness analysis
    Zeng, N.
    Han, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S369
  • [5] CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
    Zeng, Ni
    Han, Jiaqi
    Liu, Zijian
    He, Jinlan
    Tian, Kun
    Chen, Nianyong
    CANCERS, 2023, 15 (13)
  • [6] Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2-metastatic breast cancer: a systematic review and meta-analysis
    Masurkar, Prajakta P.
    Prajapati, Prachi
    Canedo, Joanne
    Goswami, Swarnali
    Earl, Sally
    Bhattacharya, Kaustuv
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (10) : 1753 - 1767
  • [7] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [8] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [9] Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2-breast cancer in Mexico
    Molina-Jaimes, Mariana
    Galindo-Gonzalez, Antonio
    Verduzco-Aguirre, Haydee Cristina
    Bautista-Arredondo, Sergio
    Reyes-Teran, Gustavo
    Soto-Perez-de-Celis, Enrique
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (01): : 239 - 244
  • [10] Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico
    Mariana Molina-Jaimes
    Antonio Galindo-González
    Haydeé Cristina Verduzco-Aguirre
    Sergio Bautista-Arredondo
    Gustavo Reyes-Terán
    Enrique Soto-Perez-de-Celis
    Clinical and Translational Oncology, 2024, 26 : 239 - 244
12345